10 August 2026
10 August 2026
Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.
ENERGI-F703DFU is currently in Phase III clinical development in both Taiwan and the US.
Under the agreement, Daiichi Sankyo handles development and supply, while Innovent Biologics leads commercialisation in China.
The approval means mFlusiva becomes the first mRNA-based vaccine to be authorised on the US market for flu prevention.
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
